Kornimate/medical-research-clean huggingface dataset:
prostate testing for cancer and treatment

Conditions: Prostate Cancer

Summary: rationale: radical prostatectomy is surgery to remove the entire prostate. radiation therapy uses high-energy x-rays or other types of radiation to kill tumor cells. sometimes the tumor may not need treatment until it progresses. in this case, active surveillance may be sufficient. it is not yet known which treatment regimen is more effective for localized prostate cancer. purpose: this randomized phase iii trial is studying active monitoring to see how well it works compared with radical prostatectomy or radiation therapy in treating patients with localized prostate cancer.

objectives: * to assess survival of patients with localized prostate cancer at 10 years and 15 years after treatment. * to investigate disease progression (i.e., biochemical and clinical), treatment complications, and lower urinary tract symptoms in these patients. * to investigate the psychosocial impact of cancer detection and treatment on these patients, including generic health status, quality of life, and sexual function. * to estimate the resource use and costs of detection, treatment, and follow-up. * to compare costs and outcomes of treatment in terms of survival and health-related quality of life. * to collect samples suitable for basic science research (prompt study). outline: this is a multicenter study. patients are stratified by age (50-55 vs 56-59 vs 60-65 vs 66-69 years), gleason score (6, 7, 8-10), and average result of recruitment and first biopsy prostate-specific antigen (psa) tests (\< 6 vs 6-9.9 vs ≥ 10 ng/ml). patients are randomized or select a treatment to be followed up in a cohort study.

Eligibility criteria:
inclusion criteria: fit for the treatments and estimates life expectancy of 10 years registration with eligible primary care practice exclusion criteria: unable to give written informed consent. concomitant or past malignancy.

Keywords: prostate cancer treatment screening surgery radiotherapy active monitoring
biology of osteosarcoma (boost) registry and biobank

Conditions: Osteosarcoma

Summary: osteosarcoma is very rare cancer of the bone. the investigator started the boost registry and biobank to make sure every patient has the opportunity to participate in research.

summary to include: 1. samples of saliva, blood and/or other stored material such as slides or leftover diagnostic material. if available the investigator may ask you for deciduous (baby) teeth. 2. questionnaire information, including health history, growth and development, physical activity and family medical history information. 3. if you have been diagnosed with a osteosarcoma or another condition the investigator is interested inthe investigator will ask you release medical record information relating to diagnosis and treatment of osteosarcoma, other cancers, blood disorders, and similar conditions. if this step applies to you then you will be asked to sign a separate form. 4. you may be asked to contact your biological parents and full biological siblings to ask them about participating in the study. 5. if you agree you may be contacted in the future. you will be able to decline any future information or studies at any point.

Eligibility criteria:
inclusion criteria: * proband inclusion criteria: a diagnosis or suspected diagnosis of osteosarcoma (iccc 9180-9200) family member inclusion criteria: biological parents and full biological siblings of a case diagnosed with osteosarcoma (iccc 9180-9200) exclusion criteria: * does not understand english.

Keywords: osteosarcoma bone cancer family-based study
the relationship of prl and polycystic ovary syndrome (pcos) in taiwan's women

Conditions: Polycystic Ovary Syndrome

Summary: polycystic ovarian syndrome (pcos) is the most common endocrine disorder of reproductive-age women. according to rotterdam 2003 criteria: at least two of three criteria are met, hyperandrogenism, chronic anovulation, and polycystic ovary. pcos will cause irregular menstrual cycle, infertility, acne, hirsutism, obesity, or/and metabolic syndrome, diabetes that may increase risk of cardiovascular disease. hyperprolactinaemia is also a common problem in reproductive aged women. both hyperprolactinaemia and pcos had endocrine disorder and irregular menstrual cycle. investigators hope to collect clinical data from pcos and prolactinemia patients followed in wang fang hospital for many years in endocrinological and metabolical aspects for comparison. investigators at the same time would like to understand more about other similarities and differences between these two endocrinological dysfunction for future study.


Eligibility criteria:
inclusion criteria: * pcom by ultrasound diagnosis * anovulation, oligo menses * hyperandrogenism exclusion criteria: * women who had been diagnosed with other etiology that should be excluded in pcos diagnosis, such as hyperprolactinemia, hypogonadotropic hypogonadism, premature ovarian failure, congenital adrenal hyperplastic, androgen-secreting tumor, cushing's syndrome, disorders of uterus( such as asherman's syndrome, mullerian agenesis), chromosomal anomalies( such as turner syndrome). * women who did not have sufficient clinical or biochemical records. * girls who had menarche at \ 40 years of age.

Keywords: pcos hyperprolactinemia obesity hyperandrogenic
airway inflammation and bronchial hyperresponsiveness in rhinitic children with or without asthma

Conditions: Rhinitis; Asthma; Inflammation; Hypersensitivity

Summary: this is a prospective observational study , to clarity the characteristics of airway inflammation, airway reactivity and airway resistance in rhinitic children with or without asthma and to explore the possible predictors in the progression of allergic rhinitis to asthma.

children 6-15 years old with allergic rhinitis and/or asthma diagnosed by specialist physician are enrolled in the department of respiratory and otorhinolaryngology and pediatrics in guangzhou institute of respiratory disease. according to presence of typical symptoms and signs, patients are divided into allergic rhinitis without asthma (ar group) , allergic rhinitis concomitant asthma (as+ar group), asthma without rhinitis (as group). in addition, healthy students in a school are enrolled as normal control group. history of all subjects are collected, the following measurements are performed: skin prick test (spt), peripheral blood cells five-classification test, serum total immunoglobulin e (ige) and specific ige of common inhalant allergens testing, nasal lavage and induced sputum cells classification ，pulmonary function test, bronchial provocation test using methacholine，airway resistance measured by impulse oscillation technique, the levels of eosinophil（ecp），eosinophil peroxidase（epo）.meanwhile myeloperoxidase （mpo）and eosinophil-derived neurotoxin (edn) are measured in induced sputum ,in nasal lavage and in serum.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of allergic rhinitis and/or asthma * sensitized to more than 1 common aeroallergens exclusion criteria: * respiratory infection 2 weeks prior to initial visit * children with nasal polyposis * history of immunotherapy * unable to complete the test or had limited understanding * use of systemic corticosteroids 4 weeks prior to initial visit * nasal and inhaled corticosteroids 2 weeks prior to initial visit * leukotriene receptor antagonists 2 weeks prior to initial visit

Keywords: child allergic rhinitis asthma nitric oxide bronchial hyper-responsiveness
cognitive and psychosocial outcome after mild traumatic brain injury

Conditions: Mild Traumatic Brain Injury

Summary: patients with traumatic brain injury are likely to present with cognitive, psychological, emotional and behavioral problems during different periods, all of which affect patients' life quality seriously. the aim of this study was to assess cognitive and psychosocial outcome in patients with mild traumatic brain injury, and to determine the risk factors associated with cognitive and psychological outcome. mini-mental state examination (mmse), activities of daily living scale (adl), the hospital anxiety depression scale (hads) and mental health symptom checklist (scl-90) were used to assess the cognitive performance and psychological outcomes in 360 patients with mild traumatic brain injury. chi-square, fisher's exact tests and logistic regression analysis were used to analyze the risk factors.


Eligibility criteria:
inclusion criteria: * 18 \~ 60 years old * education: primary school and above, who could understand the content of psychological test * history of brain trauma * no taking of antipsychotic or any other drugs affecting central nervous system before the test * glasgow coma score (gcs) was 13-15 exclusion criteria: * history of craniocerebral injury, brain disease, mental disease * with mental retardation * with other serious body diseases * history of drug and alcohol dependence * with color-blind or color weakness * who had severe visual and auditory disorders after brain injury * who failed or failed in completing the test effectively * with cognitive impairment caused by the damage of the unilateral frontal or bilateral lobes, or with language dysfunction caused by temporal lobe damage

Keywords: mild traumatic brain injury cognitive outcome psychological outcome
monitoring of hydration status in chronic hemodialysis patients

Conditions: Hemodialysis; Kidney Failure; Overhydration

Summary: background maintaining fluid balance is one of major challenges of the dialysis therapy. it includes, in particular, the management of "dry body mass". we postulated that simple measurement of subscapular skinfold thickness before and after hemodialysis could help monitor hydration status in chronic dialysis patients. aim of the study the aim of the study was to compare the conventional methods of monitoring hydration status during hemodialysis with an assessment of skin fold thickness. materials and methods 50 participants (21 f, 29 m; age 60 ±15 years) were enrolled. directly before the hemodialysis session the following parameters were measured: body composition with bioimpedance spectroscopy, skinfold thickness in subscapular area with standardized caliper and blood tests: blood count, urea, n-terminal pro b-type natriuretic peptide (nt-probnp) and pro-adrenomedullin (pro-adm). the procedures were repeated at the end of three consecutive hemodialysis sessions.


Eligibility criteria:
inclusion criteria: * chronic hemodialysis for at least 3 months exclusion criteria: * severe mental disabilities, poor compliance, any acute infection, instability of the cardiovascular hemodynamic condition

Keywords: hemodialysis water-electrolyte balance dry body mass skinfold thickness
artificial intelligence-assisted common bile duct stent selection in endoscopic retrograde cholangiopancreatography

Conditions: Stenosis of Bile Duct; Endoscopic Retrograde Cholangiopancreatography

Summary: common bile duct stenosis is an important indication for endoscopic retrograde cholangiopancreatography(ercp). appropriate selection of bile duct stent size is not only conducive to successful stent implantation but also to improve the prognosis of patients. currently, the selection of stent specifications is based on the operator's empirical estimation, which is not only not accurate but also increases the radiation exposure time, causing unnecessary harm to both the operator and the patient. our objective is to develop an artificial intelligence algorithm to automatically select appropriate stent.

endoscopic retrograde cholangiopancreatography (ercp) is an operation with high risk. common bile duct stone and stenosis are important indications. the quality control of ercp is the key to improve its success rate and reduce complications, which has received great attention. in 2015, the american society of gastrointestinal endoscopy/american college of gastroenterology (asge/acg) issued ercp quality control indicators, among which biliary stent placement and radiographic fluoroscopy time are important intraoperative quality control indicators. the selection of appropriate biliary stent size is not only conducive to successful stent implantation but also to improve the prognosis of patients. choose a stent of appropriate length. the proximal side of the stent should be 1cm above the obstruction segment, and the distal tail should be located just outside the nipple. the length of the stent can be determined by measuring the distance between the proximal end of the obstruction and the nipple under x-ray. current stent size selection is based on the operator's empirical estimation :(1) estimate the distance by endoscope diameter or cone length or catheter marking; (2) by retracting the guidewire, calculate the distance of the guidewire retracting between two points to estimate the length of the stent.the long radiation exposure time results in unnecessary injuries to both the operator and the patient.

Eligibility criteria:
inclusion criteria: * patients older than 18 years old who underwent ercp exclusion criteria: * failed cholangiopancreatography caused by failed intubation, gastric retention, duodenal disease and so on * patients proved no stenosis in common bile duct * poor cholangiograms due to the lack of contrast agent or insufficient filling of contrast agent (cholangiograms without the completed cbd or thumbnails)
pediatric ease of use ellipta items

Conditions: Asthma

Summary: a range of devices has been developed to administer inhaled therapy for asthma, including dry powder inhaler (dpi) devices. ellipta is a dpi that is preloaded with a drug therapy to treat asthmatic subjects. the objective of this study is to revise ease of use items developed for adults to be appropriate for completion by pediatric subjects in future clinical trials and to evaluate the newly developed items in subjects with asthma aged 5 to 11 years and their caregivers. this is a cross-sectional, qualitative study that will involve pediatric subjects with asthma who are currently using an asthma maintenance inhaler and their caregivers. two rounds of repetitive cognitive interviews will be conducted with 16 subjects in each interview set. each interview will last approximately 45 minutes. data provided by pediatric subjects and their caregivers during interview will be collected as field notes and audio recordings which will be transcribed.


Eligibility criteria:
inclusion criteria: child inclusion criteria * be 5 to 11 years of age * have asthma * currently use a maintenance inhaler to treat their asthma * be willing and able to provide assent * be willing and able to participate in a 45-minute interview in english caregiver inclusion criteria * above 18+ years of age * be a caregiver (parent or legal guardian) of a pediatric subject with asthma that meets the criteria above * be willing and able to provide signed and dated informed consent and parental permission in english * be willing and able to participate in a 45-minute interview exclusion criteria: * nil

Keywords: caregiver ellipta asthma dry powder inhaler pediatric
a study to evaluate the efficacy and safety of two dose levels of certolizumab pegol (czp) in subjects with plaque psoriasis (pso)

Conditions: Psoriasis; Plaque Psoriasis

Summary: the purpose of this study is to investigate the efficacy and safety of two dose levels of certolizumab pegol in adults with moderate to severe chronic plaque psoriasis.

this study consists of the following periods: * initial treatment period from week 0 to week 16 * maintenance treatment period from week 16 to week 48 * open-label treatment period from week 48 to week 144 * safety follow-up period from week 144 to week 152

Eligibility criteria:
inclusion criteria: * provided informed consent * adult men or women \>= 18 years * chronic plaque psoriasis for at least 6 months * baseline psoriasis activity and severity index \>= 12 and body surface area \>= 10 % and physician's global assessments score \>= 3 * candidate for systemic psoriasis therapy and/or phototherapy and/or chemophototherapy * other protocol-defined inclusion criteria may apply exclusion criteria: * erythrodermic, guttate, generalized pustular form of psoriasis * history of current, chronic, or recurrent infections of viral, bacterial, or fungal origin as described in the protocol * congestive heart failure * history of a lymphoproliferative disorder including lymphoma or current signs and symptoms suggestive of lymphoproliferative disease * concurrent malignancy or a history of malignancy as described in the protocol * history of, or suspected, demyelinating disease of the central nervous system (e.g., multiple sclerosis or optic neuritis) * female subjects who are breastfeeding, pregnant, or plan to become pregnant during the study or within 3 months following last dose of study drug. male subjects who are planning a partner pregnancy during the study or within 10 weeks following the last dose * any other condition which, in the investigator's judgment, would make the subject unsuitable for participation in the study * other protocol-defined exclusion criteria may apply

Keywords: certolizumab pegol cimzia psoriasis
evluation of thyroid functions in hemodialysis childern in sohag university hospital

Conditions: Chronic Renal Failure

Summary: thyroid gland and its hormones play an important role in organ development and the homeostatic control of many physiological mechanisms such as body growth and energy expenditure. the two main thyroid hormones are triiodothyronine (t3) and thyroxine (t4) affect renal development and metabolism so any impairment in thyroid functions lead to or aggravate kidney diseases. on the other hand, kidneys play an important role in the thyroid metabolism as it normally contributes to the clearance of iodide, primarily by glomerular filtration. among patients with renal failure, there is diminished iodide excretion and an increase in plasma inorganic iodide, which results in increased uptake of the iodide by the thyroid gland. increases in total body inorganic iodide can potentially block thyroid hormone production (the wolff-chaik off effect). such a change may explain the slightly higher frequency of goiter and hypothyroidism in patients with chronic kidney diseases. the kidneys affect the hypothalamic pituitary-thyroid axis, so any impairment in kidney functions leads to disturbed thyroid physiology. all levels of the hypothalamic-pituitary-thyroid axis may be involved, including alterations in hormone production, distribution, and excretion. end stage renal disease (esrd) and hemodialysis (hd) affect the levels of all thyroid hormones. the earliest and the most common thyroid function abnormality in patients with esrd on hd is low t3 level (especially total t3 than free t3). this is called 'low t3 syndrome. the prevalence of subclinical hypothyroidism has been reported to be much higher in patients with esrd on hd than in the general population. due to similarity of signs and symptoms, sometimes it is difficult to identify subjects with esrd also has hypothyroidism; therefore, different studies have been carried out to establish the incidence of these conditions.


Eligibility criteria:
inclusion criteria: * children started hemodialysis for end stage renal disease at age of 2 to 16 years will be included in the study. exclusion criteria: * patients with known thyroid disease. patients with a history of autoimmune disease .
efficacy, safety and tolerability of a novel malathion formulation in patients 2 years and older with head lice

Conditions: Pediculosis

Summary: in this study, malathion gel 0.5% will be compared to nix (permethrin 1%) as a treatment for head lice in patients 2 years of age and older. malathion gel 0.5% is a new formulation of an established head lice treatment. the new formulation has been evaluated in 2 previous studies of patients 2 years of age and older.

this is a phase iii, multi-center, investigator-blinded, two-arm, randomized, parallel group study, evaluating the safety and efficacy of a malathion gel, 0.5% formulation, manufactured by taro. the objective is to show superiority of the novel product to an active control, nix® crème rinse, manufactured by insight pharmaceuticals.

Eligibility criteria:
inclusion criteria: * confirmed active head lice infestation exclusion criteria: * allergy to pediculicides or hair care products * scalp conditions other than head lice * previous head lice treatment within the past 4 weeks * current antibiotic treatment

Keywords: head lice
covid-19 huashi baidu formula clinical study

Conditions: COVID-19

Summary: combined with the regional and population characteristics of asia and africa, huashi baidu granule was used to intervene in mild and moderate patients with covid-19, evaluate its efficacy and safety, and clarify its characteristics of action.

in this study, a double-blind, double dummy, randomized control method was used to include 300 cases of mild and moderate covid-19 patients in three centers at home and abroad. the clinical efficacy of huashi baidu granule and monapiravir in intervening covid-19 patients was compared, it is proved that huashi baidu granule has the same clinical efficacy and safety against covid-19 as monapiravir, and its characteristics of action are clarified to obtain high-level clinical evidence-based medical evidence of huashi baidu granule in treating covid-19 mild and moderate.

Eligibility criteria:
inclusion criteria: 1. conform to the diagnostic criteria for covid-19 mild and moderate in the guidelines for the diagnosis and treatment of novel coronavirus (covid-19) infection (trial version 10) ； 2. age ≥ 18 years and ≤ 65 years; 3. the time from the first symptom (or confirmed onset) shall not exceed 5 days; 4. if the patient agrees to participate in the study, he/she will sign the informed consent form through paper signature, electronic signature of mobile software or voice authorization. exclusion criteria: 1. patients who cannot guarantee the compliance of taking medicine during the treatment period, and who are difficult to take medicine by oral or nasal feeding. 2. patients with severe primary respiratory diseases or other pathogenic microorganism pneumonia that needs to be differentiated from covid-19. 3. pregnant women, with positive urine pregnancy test, or with pregnancy plan within 12 months. 4. patients suffering from malignant tumors, mental diseases and other systematic malignant diseases that the researchers consider unsuitable for the study. 5. people who have ever been allergic to the test drug and who do not tolerate the drug. 6. those who are participating in other clinical trials. 7. non severe patients in the trial shall not enter the study again after changing the classification.

Keywords: huashi baidu granule randomized controlled trial evidence-based